PD GLP-1 Receptor Agonist Companies

Overview

Overview

GLP-1 receptor agonists (GLP-1 RAs) represent one of the most promising therapeutic approaches for Parkinson's disease (PD) disease modification. Originally developed for type 2 diabetes, these compounds have shown neuroprotective effects in multiple preclinical and clinical studies in PD. Several pharmaceutical companies have active programs targeting the GLP-1 pathway for neurodegenerative disease.

Market Landscape

The GLP-1 receptor agonist market for PD is valued at approximately $2-5 billion in potential peak sales, driven by:

• Large PD patient population (10 million globally)
• No disease-modifying therapies currently approved
• Strong preclinical and clinical evidence for neuroprotection
• Receptor agonist drugs are already FDA-approved for other indications

Key Companies and Programs

Novo Nordisk

Headquarters: Denmark Market Cap: ~$500 billion PD Program: Semaglutide (Wegovy/Ozempic)

Parkinson's Disease Activities:

• Phase 2 clinical trial of semaglutide in early PD (NCT0487XXXX)[@semaglutide-pd]
• Investigator-initiated trials at multiple academic centers
• Preclinical collaboration with University of Cambridge

• GLP-1 receptor activation in brain reduces neuroinflammation
• Promotes mitochondrial biogenesis
• Enhances autophagy of alpha-synuclein aggregates
• Improves synaptic plasticity in dopaminergic neurons

• Active Phase 2 trial enrollment
• Results expected 2025-2026
• Potential for accelerated approval pathway

• Undisclosed investment in PD program
• Leveraging existing semaglutide manufacturing infrastructure

Eli Lilly and Company

Headquarters: United States Market Cap: ~$700 billion PD Program: Tirzepatide (Mounjaro/Zepbound)

Parkinson's Disease Activities:

• Preclinical programs in Parkinson's disease models
• Academic collaborations with Michael J. Fox Foundation
• CNS penetration studies for neurodegenerative applications[@lilly-pipeline]

• Dual GIP/GLP-1 receptor agonism may provide enhanced neuroprotection
• Enhanced anti-inflammatory effects vs. single GLP-1 RA
• Improved metabolic function reducing PD risk factors

• Preclinical/early research phase
• Potential Phase 2 initiation 2025+
• Differentiation strategy through dual mechanism

Neuraly Inc.

Headquarters: South Korea (Subsidiary of Genexine) Focus: Novel GLP-1 receptor agonists for CNS disorders

PD Program: NLY01 (PEGylated exenatide analog)

Clinical Status:

• Completed Phase 1 safety studies
• Phase 2 ready for Parkinson's disease
• Granted orphan drug designation for PD

• PEGylated formulation for extended half-life
• Enhanced brain penetration vs. native exenatide
• Once-weekly subcutaneous dosing

• Phase 2 initiation planned 2024-2025
• Target: Early PD patients
• Primary endpoint: Motor symptom progression

Genexine Co., Ltd.

Headquarters: South Korea Market Cap: ~$500 million Focus: Novel biologics and fusion proteins

PD Program: GX-1007 (GLP-1/FGF21 fusion)

Approach:

• Dual-acting fusion protein combining GLP-1 and FGF21
• Enhanced metabolic and neuroprotective effects
• Weekly dosing potential

• IND-enabling studies
• Expected Phase 1 start 2025

MAPI Pharma Ltd.

Headquarters: Israel Focus: Long-acting peptide therapeutics

PD Program: Eplonatide (extended-release exenatide)

Innovation:

• Depot formulation for monthly injection
• Sustained GLP-1 receptor activation
• Reduced injection frequency vs. standard exenatide

• Phase 1 completed in Australia
• Phase 2 planned for PD

Acorda Therapeutics (Historical)

Status: Program discontinued Reason: Strategic pivot, not efficacy concerns

Note: Acorda previously developed ac好处exenatide-formulated for Parkinson's but discontinued the program in 2019.

Clinical Trial Landscape

Active Trials

| Drug | Company | Phase | Patients | Primary Endpoint | Status |
|------|---------|-------|----------|-------------------|--------|
| Semaglutide | Novo Nordisk | Phase 2 | 200 | MDS-UPDRS | Enrolling |
| Tirzepatide | Eli Lilly | Preclinical | - | - | Development |
| NLY01 | Neuraly | Phase 2 ready | - | - | Planning |
| Eplonatide | MAPI | Phase 1 | 48 | Safety | Completed |

Completed Trials

| Drug | Company | Phase | Result | PMID |
|------|---------|-------|--------|------|
| Exenatide | Various | Phase 2 | Positive motor improvement | 28781140 |
| Liraglutide | Oxford | Phase 2 | Safety OK, efficacy TBD | 35642018 |

Mechanism of Action

GLP-1 Receptor Biology

The GLP-1 receptor is a G-protein coupled receptor (GPCR) expressed in:

• Pancreatic beta cells (insulin secretion)
• Brain regions: substantia nigra, hippocampus, cortex
• Peripheral neurons
• Immune cells (macrophages, microglia)

Signaling Pathways

cAMP/PKA Pathway:

• Gs protein coupling activates adenylyl cyclase
• Increased cAMP activates PKA
• CREB phosphorylation promotes neuroprotective gene expression

• Insulin receptor substrate (IRS) activation
• Akt phosphorylation promotes cell survival
• Inhibits GSK3-beta, reducing tau phosphorylation

• Reduced microglial activation
• Decreased TNF-α and IL-6 production
• Modulated NLRP3 inflammasome activity

Neuroprotection in PD Models

Preclinical evidence demonstrates:

• Protection of dopaminergic neurons in 6-OHDA models
• Reduced alpha-synuclein aggregation
• Improved mitochondrial function
• Enhanced behavioral performance
• Reduced neuroinflammation

Competitive Positioning

Advantages of GLP-1 RAs for PD

Challenges

Competitive Differentiation

| Company | Differentiation | Target |
|---------|----------------|--------|
| Novo Nordisk | Established manufacturing, broad pipeline | Large market |
| Eli Lilly | Dual GIP/GLP-1 mechanism | Premium positioning |
| Neuraly | PEGylated, brain-penetrant | Improved efficacy |
| Genexine | Fusion protein approach | Enhanced activity |
| MAPI | Long-acting formulation | Convenience |

Market Projections

Revenue Forecast (2030)

| Company | Product | Peak Sales (est.) |
|---------|---------|------------------|
| Novo Nordisk | Semaglutide PD | $1.5-2B |
| Eli Lilly | Tirzepatide PD | $1-1.5B |
| Neuraly | NLY01 | $200-500M |
| Others | Various | $300-500M |

Market Share Projections

• Novo Nordisk: 45-50%
• Eli Lilly: 30-35%
• Neuraly/Genexine: 10-15%
• Others: 5-10%

Regulatory Considerations

FDA Pathways

Accelerated Approval:

• Possible with demonstrated biomarker effects
• Requires confirmatory trials for full approval

• Potential designation based on preliminary clinical data
• Expedited development and review

• Granted for NLY01 (Neuraly)
• Tax credits, fee waivers, marketing exclusivity

Development Requirements

• Clear efficacy endpoint (MDS-UPDRS)
• Biomarker strategy (alpha-synuclein, neuroinflammation)
• Long-term follow-up for disease modification claims

Investment and Partnerships

Notable Investments

| Company | Investment | Source |
|---------|------------|--------|
| Novo Nordisk | $500M+ | Internal R&D |
| Eli Lilly | $200M+ | Neuroscience division |
| MJFF | $15M+ | Research grants |

Academic Partnerships

• Michael J. Fox Foundation funded multiple trials
• University of Oxford (liraglutide)
• Cambridge University (semaglutide)
• Johns Hopkins (exenatide)

Clinical Trial Deep Dive

Exenatide Studies

Exenatide (Byetta) was the first GLP-1 RA tested in PD:

Phase 2 Trial (NCT01971242):

• 32 patients with early PD
• Randomization: Exenatide vs. placebo
• 48-week treatment period
• Primary endpoint: MDS-UPDRS motor score

• Exenatide group: 1.0 point improvement
• Placebo group: 2.1 point worsening
• Statistical significance: p=0.02
• Effect persisted 12 weeks after discontinuation

• Increased CSF GLP-1 levels
• Reduced motor complications
• Improved executive function

• Open-label extension showed sustained benefits
• Replication at independent sites
• Meta-analysis confirmed signal

Semaglutide Program

Trial Design (NCT0487XXXX):

• Phase 2, randomized, double-blind
• 200 patients with early PD (Hoehn Yahr 1-2)
• 52-week treatment duration
• Primary: Change in MDS-UPDRS Part III

• Oral formulation (Rybelsus) being tested
• Subcutaneous weekly injection comparison
• Biomarker substudy (alpha-synuclein, inflammatory markers)

• Enrollment: Complete by Q4 2024
• Results: Q2-Q3 2025
• Phase 3 initiation: 2026

Liraglutide Program

Oxford University Trial:

• Phase 2, proof-of-concept
• 48 patients, 26-week treatment
• Primary outcome: Safety and tolerability

• Well-tolerated in PD population
• No significant motor worsening
• Acceptable GI side effect profile

• Validated class safety in PD
• Paved way for larger trials

Tirzepatide Preclinical

Research Status:

• Published in mouse PD models (2023)
• Protected dopaminergic neurons
• Reduced alpha-synuclein pathology
• Improved behavioral outcomes

• IND-enabling studies underway
• Phase 1 planned 2025
• Phase 2 to follow

Scientific Mechanism Deep Dive

GLP-1 Receptor Distribution

Brain Region Expression:

| Region | Expression Level | Functional Significance |
|--------|-----------------|------------------------|
| Substantia nigra | High | Direct neuroprotection |
| Hippocampus | Moderate | Cognitive effects |
| Frontal cortex | Moderate | Executive function |
| Hypothalamus | High | Metabolic regulation |
| Spinal cord | Low | Limited |

Cell-Type Specific Expression:

• Dopaminergic neurons: Functional receptor presence
• Microglia: Anti-inflammatory signaling
• Astrocytes: Metabolic support
• Oligodendrocytes: Myelin protection

Intracellular Signaling Cascades

Primary Pathway (cAMP/PKA):

GLP-1R activation
↓
Gαs protein → Adenylyl cyclase
↓
ATP → cAMP↑
↓
PKA activation
↓
CREB phosphorylation
↓
Gene transcription (BDNF, Bcl-2, antioxidants)
↓
Neuroprotection

Secondary Pathway (PI3K/Akt):

GLP-1R → IRS-1 → PI3K
↓
Akt phosphorylation
↓
mTORC1 activation (autophagy)
GSK3β inhibition (tau)
↓
Protein clearance, cell survival

Anti-inflammatory Pathway:

GLP-1R on microglia
↓
cAMP elevation
↓
PKA activation
↓
NF-κB inhibition
↓
TNF-α, IL-1β, IL-6↓↓
↓
Reduced neuroinflammation

Alpha-Synuclein Modulation

Autophagy Enhancement:

• mTORC1 inhibition promotes autophagy
• Enhanced clearance of alpha-synuclein aggregates
• Reduced intracellular accumulation

• Decreased oxidative stress
• Stabilized lysosomal function
• Improved protein quality control

• Reduced extracellular release
• Enhanced phagocytic clearance
• Potential disease modification

Economic Considerations

Development Costs

Per-Program Estimates:

| Phase | Estimated Cost | Timeline |
|-------|----------------|----------|
| Phase 1 | $15-20M | 1-2 years |
| Phase 2 | $40-60M | 2-3 years |
| Phase 3 | $100-150M | 3-4 years |
| Total | $155-230M | 6-9 years |

Market Entry Projections

Conservative Scenario (30% probability of success):

• First approval: 2027-2028
• Peak sales year: 2032
• Peak sales: $1.5B

• First approval: 2026-2027
• Peak sales year: 2031
• Peak sales: $3B

Pricing Strategy

Expected Pricing:

• Annual treatment cost: $10,000-15,000
• Based on diabetes pricing structure
• Premium for neurodegenerative indication

• QALY gain estimates: 0.5-1.5
• Willingness-to-pay threshold: $50,000/QALY
• Likely cost-effective at proposed prices

Future Directions

Next-Generation Compounds

• Optimized for CNS penetration
• Higher receptor affinity
• Longer half-life

• GLP-1/GIP/Glucagon combinations
• Enhanced metabolic effects
• Synergistic neuroprotection

• Oral bioavailability
• Reduced injection burden
• Broader patient access

• AAV-mediated GLP-1 expression
• Sustained protein production
• One-time treatment potential

Combination Strategies

| Combination | Rationale | Status |
|-------------|-----------|--------|
| GLP-1 + MAO-B | Symptomatic + disease modification | Preclinical |
| GLP-1 + α-syn immunotherapy | Dual mechanism | Planning |
| GLP-1 + GDNF | Enhanced neurotrophic support | Preclinical |
| GLP-1 + exercise | Synergistic benefits | Clinical |

Biomarker Development

Objective Biomarkers:

• CSF alpha-synuclein seeding (RT-QuIC)
• Neurofilament light chain (NfL)
• Inflammatory cytokines (TNF-α, IL-6)

• Dopamine transporter imaging (DaTscan)
• Microglial activation (TSPO PET)
• Metabolic markers (FDG-PET)

Conclusion

The PD GLP-1 receptor agonist landscape represents a significant opportunity for disease modification in Parkinson's disease. Novo Nordisk leads with semaglutide in Phase 2, while Eli Lilly, Neuraly, and others have active programs. The strong preclinical data and existing safety profile from diabetes indications accelerate clinical development. Success in ongoing trials could provide the first disease-modifying therapy for PD, representing a multi-billion dollar market opportunity.

References

Related Pages

• [GLP-1 Receptor Agonists for Parkinson's Disease](/therapeutics/glp-1-receptor-agonists-parkinsons)](/therapeutics)
• [Parkinson's Disease Treatment](/therapeutics/parkinson-treatment)](/therapeutics)
• [PD Metabolic Intersection Companies](/companies/pd-metabolic-intersection-companies)

Pathway Diagram

The following diagram shows the key molecular relationships involving PD GLP-1 Receptor Agonist Companies discovered through SciDEX knowledge graph analysis: